Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan - Summary - MDSpire
Advertisement
Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan
To assess long-term alterations in monthly migraine days (MMDs), patient-reported outcomes (PROs) including MIDAS, HIT-6, and VAS, treatment adherence, and factors leading to discontinuation of anti-CGRP monoclonal antibodies.
Key Findings:
MMDs reduced from 12.0 ± 5.4 to 5.6 ± 5.4 at 36 months among those who persisted with therapy (p < 0.01).
Responder rates at 36 months were ≥50%: 55.6%, ≥75%: 29.6%, 100%: 11.1%.
24% of treatment cessations were due to achieving treatment objectives, with no discontinuations due to adverse events.
Interpretation:
Anti-CGRP monoclonal antibodies demonstrated sustained efficacy and tolerability over three years, supporting personalized treatment decisions based on individual patient responses.
Limitations:
Small sample size of 50 patients may limit the robustness of findings.
Single-center study may limit generalizability and introduce potential biases.
Conclusion:
The study reinforces the long-term benefits of anti-CGRP monoclonal antibodies in migraine prevention, highlighting the importance of personalized treatment strategies.
